On February 16, 2022, FDA revealed a compounding threat notify describing the probable threats related to at-household use of compounded ketamine nasal spray and a number of other adverse party reports. The February 2022 compounding chance notify also provided information about Spravato, which can be topic to some Risk Analysis and Mitigation Syste… Read More